Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes

Phase 4

Completed

• Conditions: Endothelial Graft Rejection
• Interventions: Drug: Sandimmune; Drug: Artelose

• Registration Number: NCT01028443
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the rejection.

Detailed Description

Not available

Study Timeline

• Status Verified: 2006-04
• Study First Submitted: 2009-12-08
• Study First Submitted QC: 2009-12-08
• Last Update Submitted: 2009-12-08
• Study First Posted: 2009-12-09
• Last Update Posted: 2009-12-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Penetrating keratoplasty in eyes without vascularization

Exclusion Criteria

• History of previous intraocular surgery

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Cyclosporine A 2%	Sandimmune	-
Artificial tears	Artelose	-

Primary Outcome Measures

Name	Time	Method
The rate of rejection after drop sessation	3 years

Trial Locations

Locations (1)

Ophthalmic Research Center; 🇮🇷 Tehran, Iran, Islamic Republic of